Sofwave Medical Ltd.

What kind of company is Sofwave Medical?

Sofwave Medical is a publicly traded medical device company that develops and sells non-invasive ultrasound systems for skin rejuvenation and muscle toning, used by dermatologists and aesthetic physicians.

Is Sofwave Medical publicly traded?

Yes. It trades on the Tel Aviv Stock Exchange under ticker SOFW and over-the-counter in the US under SOFWF. It listed in May 2021.

Who owns Sofwave Medical?

The company is publicly held by institutional, retail, and insider shareholders. Co-founder and chairman Shimon Eckhouse and CTO Ariel Sverdlik remain key insiders; no single entity controls the company.

How much revenue does Sofwave Medical make?

FY2025 revenue was $87.6 million, up 46.9 percent, with trailing twelve-month revenue of $104.4 million as of Q2 2026 and FY2025 net income of approximately $18.9 million.

Where is Sofwave Medical headquartered?

The company is headquartered at 1 Ha-Otsma Street in Yokneam Illit, Northern District, Israel.

How many employees does Sofwave Medical have?

151 employees as of late 2026, up about 20 percent year over year, with most growth in North American commercial operations.

What does Sofwave Medical sell?

Its main product is the SUPERB ultrasound system for skin lifting and wrinkle reduction, plus the Pure Impact VIP muscle toning platform and recurring single-use treatment tips.

Eckhouse and Sverdlik incorporated Sofwave Medical on January 27, 2015, in the Yokneam Illit high-tech zone. The founding concept was a new ultrasound architecture that could produce controlled mid-dermal heating for collagen remodeling while protecting the skin surface, aiming for visible lifting without the pain, downtime, or fat-loss risks associated with first-generation ultrasound and RF devices.

The early years were spent on engineering, clinical trials, and regulatory work. The resulting SUPERB platform, Synchronous Ultrasound Parallel Beam technology with integrated SofCool surface cooling, won FDA clearance for improving facial lines and wrinkles, later extended to brow lifting and laxity of submental and neck tissue.

Commercialization accelerated after the May 2021 Tel Aviv listing. Revenue compounded from $21.8 million (2021) through $35.6 million (2022), $50.3 million (2023), $59.7 million (2024), and $87.6 million (2025). Quarterly growth continued into 2026, with Q2 revenue of $30.0 million up 42.7 percent year over year.

The company broadened its platform with Pure Impact VIP, a non-invasive muscle toning technology, moving beyond skin into body aesthetics. Headcount reached 151 by late 2026, up about 20 percent in a year, with expansion concentrated in North American commercial operations.

The company has received recognition within medical aesthetics industry events and dermatology trade media, and its SUPERB platform holds multiple FDA clearances and CE marking. Founder Eckhouse's standing as a pioneer of energy-based aesthetics is itself a form of institutional recognition the company leverages commercially.